Elevated pretreatment levels of soluble CD8 and β-2 microglobulin as indicators of relapse in breast cancer patients

B. Klein*, I. Levin, H. Lurie, A. Nyska, J. Shapira, M. Kravits, T. Klein

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

We measured soluble CD8 (s)CD8) and β-2 microglobulin (β-2M) in 128 breast cancer patients and in 200 controls by the ELISA method. Patient groups were: Group A-new patients; Group B-patients on follow-up; Group C-patients with metastases. The mean (s)CD8 and β-2M were significantly higher in patients than in controls (s)CD8 p < 0.01, β-2M p < 0.0001). Both for (s)CD8 and β-2M, groups A and C had high levels which differed significantly from Group B (s)CD8 p < 0.04; β-2M p < 0.0001). A significant correlation between (s)CD8 and β-2M was observed (r = 0.379; p = 0.0001). Twenty patients relapsed. In 14/20 (70%) an initial high (s)CD8 and in 10/20 (50%), high β-2M was observed. High initial (s)CD8 andβ-2M were able to identify 80% of relapsed patients. High (s)CD8 and β-2M levels are indicative of tumor bulk and are able to identify patients at high risk for relapse.

Original languageEnglish
Pages (from-to)471-474
Number of pages4
JournalInternational Journal of Oncology
Volume4
Issue number2
StatePublished - 1994
Externally publishedYes

Keywords

  • B-2 microglobulin
  • Breast cancer
  • Soluble CD8

Fingerprint

Dive into the research topics of 'Elevated pretreatment levels of soluble CD8 and β-2 microglobulin as indicators of relapse in breast cancer patients'. Together they form a unique fingerprint.

Cite this